Pharmacology and Toxicology
Pharmacology and Toxicology
Assistant Professor, BIO5 Institute, Associate Professor, Pharmacology and Toxicology
Associate Dean, Research and Graduate Studies - College of Pharmacy, Director, Southwest Environmental Health Science Center, Professor, BIO5 Institute, Professor, Clinical Translational Sciences, Professor, Pharmacology and Toxicology, Professor, Public Health
Head, Pharmacology and Toxicology, Professor, BIO5 Institute, Professor, Pharmacology and Toxicology
Xinxin Ding, PhD, department head, Pharmacology and Toxicology, College of Pharmacy—studies enzyme function, regulation and genetics as applied to translational research for drug safety and efficacy and genetic and environmental risks for chemical toxicity. Author of nearly 200 peer-reviewed papers, book chapters and articles, he serves as associate editor for “Drug Metabolism and Disposition” and “Acta Pharmaeutica Sinica B.” Grants from the National Cancer Institute and National Institute of Environmental Health Sciences of the National Institute of Health fund his work, in part. Former chair of the NIH XNDA study section (2016-2018), he currently chairs (2018-19) Drug Metabolism and Disposition Division of the American Society for Pharmacology and Experimental Therapeutics..
Assistant Research Scientist, Cancer Center Division, Associate Professor, BIO5 Institute, Investigator, Center for Toxicology, Professor, Pharmacology and Toxicology, Professor, Cancer Biology - GIDP
Bernard Futscher's lab is studying the molecular origins of human cancer. Understanding epigenetic dysfunction in human cancer has been Dr. Futscher's primary research focus since establishing his own independent laboratory. This epigenetic research has moved into the area of noncoding RNAs and their potential role in cancer cell immortality.
Assistant Professor, Pharmacology and Toxicology
Professor, BIO5 Institute, Professor, Pharmacology and Toxicology
The Hulme group is focused on small molecule drug design and developing enabling chemical methodologies to expedite the drug discovery process. The development of small molecule inhibitors of kinases is of particular interest.
Associate Director, BIO5 Institute, Professor, BIO5 Institute, Professor, Medicinal Chemistry-Pharmaceutical Sciences, Professor, Medicinal Chemistry-Pharmacology and Toxicology, Professor, Cancer Biology - GIDP
Laurence Hurley's long-time research interest is in molecular targeting of DNA, first by covalent binders (CC-1065 and psorospermin), then as compounds that target protein–DNA complexes (pluramycins and Et 743), and most recently as four-stranded DNA structures (G-quadruplexes and i-motifs). He was the first to show that targeting G-quadruplexes could inhibit telomerase (Sun et al.  J. Med. Chem., 40, 2113) and that targeting G-quadruplexes in promoter complexes results in inhibition of transcription (Siddiqui-Jain et al.  Proc. Natl. Acad. Sci. U.S.A., 99, 11593).
Adjunct Associate Professor, Nursing, Assistant Professor, Medicine - (Research Scholar Track), Associate Professor, BIO5 Institute, Associate Professor, Genetics - GIDP, Associate Professor, Pharmacology and Toxicology, Associate Professor, Public Health, Interim Associate Dean, Academic Programs and Faculty Affairs
Walter Klimecki's research program involves the balance between the particular DNA sequence “versions” of genes that we inherit from our ancestors, and the particular environmental exposures that we experience throughout our lives. The Klimecki lab studies diseases resulting from human exposure to arsenic, contributing to a better understanding of the inherited genetic differences between people that result in altered chemical processing of arsenic after it enters the body.